Patents by Inventor Paolo Senin
Paolo Senin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9623108Abstract: Formulation for oral administration, in the form of tablets or of powder for extemporaneous use, able to exert a beneficial effect on the cardiovascular system and having eulipidaemic activity, cholesterol-lowering and triglyceride-lowering activity, antioxidant activity, and a protective action on the vasal endothelium, comprising berberine in combination with a policosanol and/or red yeast and preferably containing an antioxidant, such as astaxanthin and/or folic acid.Type: GrantFiled: March 29, 2007Date of Patent: April 18, 2017Assignee: ROTTAPHARM S.p.A.Inventors: Paolo Senin, Ivo Setnikar, Luigi Angelo Rovati
-
Publication number: 20110086896Abstract: Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112° C. and melting with decomposition at about 400° C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary storage conditions. In addition its stability allows both chemical manufacturing and pharmaceutical manufacturing process consistency and reproducibility under conditions more viable and less expensive when compared to those used for highly hygroscopic solids.Type: ApplicationFiled: September 24, 2010Publication date: April 14, 2011Applicant: Rottapharm S.p.A.Inventors: Antonio GIORDANI, Antonino SANTORO, Paolo SENIN, Matteo GHIRRI, Francesco MAKOVEC, Paola GILOTTA, Walter PERIS, Lucio Claudio ROVATI
-
Patent number: 7824710Abstract: Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112° C. and melting with decomposition at about 400° C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary storage conditions. In addition its stability allows both chemical manufacturing and pharmaceutical manufacturing process consistency and reproducibility under conditions more viable and less expensive when compared to those used for highly hygroscopic solids.Type: GrantFiled: February 23, 2007Date of Patent: November 2, 2010Assignee: Rottapharm S.p.A.Inventors: Antonio Giordani, Antonino Santoro, Paolo Senin, Matteo Ghirri, Francesco Makovec, Paola Gilotta, Walter Peris, Lucio Claudio Rovati
-
Publication number: 20100028395Abstract: A composition useful for cosmetic treatment of the skin containing N-acetylglucosamine and an alkaline metal sulphate in equivalent mass ratios between 1:0.5 and 1:3, optionally in association with hyaluronic acid or a salt thereof.Type: ApplicationFiled: March 19, 2008Publication date: February 4, 2010Applicant: ROTTAPHARM S.P.A.Inventors: Paolo Senin, Antonino Santoro, Luigi Angelo Rovati
-
Publication number: 20090136469Abstract: Formulation for oral administration, in the form of tablets or of powder for extemporaneous use, able to exert a beneficial effect on the cardiovascular system and having eulipidaemic activity, cholesterol-lowering and triglyceride-lowering activity, antioxidant activity, and a protective action on the vasal endothelium, comprising berberine in combination with a policosanol and/or red yeast and preferably containing an antioxidant, such as astaxanthin and/or folic acid.Type: ApplicationFiled: March 29, 2007Publication date: May 28, 2009Applicant: ROTTAPHARM S.P.A.Inventors: Paolo Senin, Ivo Setnikar, Luigi Angelo Rovati
-
Publication number: 20080102082Abstract: Composition for oral administration, having a health-promoting effect on the cardiovascular system, comprising as active principles a policosanol or a mixture of policosanols, red yeast and an agent selected from astaxanthin and folic acid, preferably in combination with coenzyme Q10. The composition can be used in particular for the preparation of food supplements having health-promoting effects, such as eulipidaemic effect, correction of homocysteinaemia, antioxidant action and a protective effect on the vasal endothelium.Type: ApplicationFiled: September 20, 2005Publication date: May 1, 2008Applicant: ROTTAPHARM S.p.A.Inventors: Paolo Senin, Ivo Setnikar, Luigi Angelo Rovati
-
Publication number: 20070149586Abstract: Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112° C. and melting with decomposition at about 400° C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary storage conditions. In addition its stability allows both chemical manufacturing and pharmaceutical manufacturing process consistency and reproducibility under conditions more viable and less expensive when compared to those used for highly hygroscopic solids.Type: ApplicationFiled: February 23, 2007Publication date: June 28, 2007Applicant: ROTTAPHARM S.P.A.Inventors: Antonio Giordani, Antonino Santoro, Paolo Senin, Matteo Ghirri, Francesco Makovec, PaoLa Gilotta, Walter Peris, Lucio Claudio Rovati
-
Patent number: 7025998Abstract: A composition for the relief and/or prevention of climacteric and menopausal disorders affecting women in pre-, peri- or post-menopause, comprising Soy Isoflavones and viable lactic acid bacteria preferably Lactobacillus sporogenes aimed to enhance the absorption of Soy Isoflavones, the composition being provided in dosage forms for oral administration. Preferably the composition also comprises Equisetum arvense dry extract and a pharmaceutically acceptable calcium salt and/or Vitamin D3.Type: GrantFiled: May 30, 2003Date of Patent: April 11, 2006Assignee: Rotta Research Laboratorium S.p.A.Inventors: Paolo Senin, Ivo Setnikar, Angelo Luigi Rovati
-
Publication number: 20040241260Abstract: A composition for the relief and/or prevention of climacteric and menopausal disorders affecting women in pre-, peri- or post-menopause, comprising Soy Isoflavones and viable lactic acid bacteria preferably Lactobacillus sporogenes aimed to enhance the absorption of Soy Isoflavones, the composition being provided in dosage forms for oral administration. Preferably the composition also comprises Equisetum arvense dry extract and a pharmaceutically acceptable calcium salt and/or Vitamin D3.Type: ApplicationFiled: May 30, 2003Publication date: December 2, 2004Applicant: ROTTA PHARMACEUTICALS, INC.Inventors: Paolo Senin, Ivo Setnikar, Angelo Luigi Rovati
-
Patent number: 5976576Abstract: A pharmaceutical composition comprising, as active ingredient, N-4-(1H-tetrazol-5-yl)phenyl-4-(1H-tetrazol-5-yl)benzamide disodium salt (CR 2039, Andolast) or another pharmaceutically-acceptable salt thereof and a flavoring, and optionally including a pharmaceutically-acceptable inert carrier and/or a pharmaceutically-acceptable sweetener, the composition being suitable for administration by oral inhalation.Type: GrantFiled: August 6, 1998Date of Patent: November 2, 1999Assignee: Rotta Research Laboratories S.p.A.Inventors: Francesco Makovec, Paolo Senin, Lucio Claudio Rovati
-
Patent number: 4791215Abstract: New derivatives of D,L-glutamic acid and D,L-aspartic acid are described having the formulae: ##STR1## in which n is equal to 1 or 2, R.sub.1 is a phenyl group mono-, di- or tri-substituted with linear or branched C.sub.1 -C.sub.4 alkyl groups, which may be the same or different, or with halogens, with a cyano group or a trifluoromethyl group, and in which R.sub.2 is selected from the group consisting of morpholino, piperidino and amino with one or two linear, branched or cyclic alkyl group substituents containing from 1 to 8 carbon atoms, which may be the same or different, or a pharmaceutically-acceptable salt thereof.The compounds have an antagonistic activity towards bioactive polypeptides and are useful particularly in the treatment of illnesses of the digestive system and the central nervous system, as pain killers, and for the treatment of anorexia and all those affections (for example tumours) in which exogenous or endogenous bioactive polypeptides are involved.Type: GrantFiled: June 18, 1985Date of Patent: December 13, 1988Assignee: Rotta Research Laboratorium S.p.A.Inventors: Luigi Rovati, Francesco Makovec, Rolando Chiste', Paolo Senin
-
Patent number: 4642340Abstract: The compound consists of a mixed salt of glucosamine sulphate and sodium chloride corresponding to the formula: ##STR1## and is in the form of a crystalline powder with a melting point above 300.degree. C. The salt is stable at ambient temperatures and humidities and has pharmacological properties practically identical to those of glucosamine sulphate.Type: GrantFiled: April 30, 1982Date of Patent: February 10, 1987Assignee: Rotta Research Laboratorium S.p.A.Inventors: Paolo Senin, Francesco Makovec, Luigi Rovati
-
Patent number: 4576951Abstract: The subject of the invention is a new use of D,L-4-benzamido-N,N-dipropyl-glutaramic acid (proglumide) in human pain relief. According to the invention proglumide is used both alone, at dosages of from 0.5 to 30 mg/kg of body weight, and in association with analgesic-narcotic drugs, it being able to potentiate the analgesic activity of these drugs.Type: GrantFiled: December 10, 1984Date of Patent: March 18, 1986Assignee: Rotta Research Laboratorium S.p.A.Inventors: Luigi Rovati, Francesco Makovec, Paolo Senin, Pierluigi Casula
-
Patent number: 4288609Abstract: Compounds having the general formula: ##STR1## in which: Ad is 1-adamantyl (C.sub.10 H.sub.15) radicalA is oxygen atom or --NH--(imino) groupR is --CH.sub.3 (methyl) group or --C.sub.2 H.sub.5 (ethyl) groupR' is a linear aliphatic chain containing from 10 to 12 atoms of carbonX.sup.- is a halide ion.The halide may be chlorine or bromine. The compounds exhibit an antibacterial, antimould and antiprotozoic activity and may be formulated as pharmaceutical and cosmetic preparations or used as preservatives for food products.Type: GrantFiled: December 4, 1979Date of Patent: September 8, 1981Assignee: Rotta Research Laboratorium S.p.A.Inventors: Luigi Rovati, Francesco Makovec, Paolo Senin
-
Patent number: 4272538Abstract: 5-nitro-imidazole derivatives of the formula ##STR1## in which R.sub.1 is hydrogen, methyl, ethyl or phenyl, n is 2 or 3, and R.sub.2 is methyl, ethyl, carboxymethyl or carboxyethyl, and the pharamceutically acceptable acid addition salts thereof, useful as antiprotozoics.Type: GrantFiled: May 18, 1979Date of Patent: June 9, 1981Assignee: Rotta Research Laboratorium S.p.A.Inventors: Francesco Makovec, Paolo Senin, Luigi Rovati
-
Patent number: 4004008Abstract: Tyrosine derivatives of the formula: ##STR1## wherein: R.sub.1 is a linear or branched-chain alkyl group having 1-6 carbon atoms, terminating by a tertiary amino group; R.sub. 2 is an unsubstituted, monosubstituted or di-substituted phenyl or benzyloxy group, the substituent being --Cl, --Br, --NO.sub.2, --OCH.sub.3, --CH.sub.3 or --CF.sub.3 ; R.sub.3 is a primary, secondary or tertiary amino group or an aryl-alkylamino group having 7-9 carbon atoms; and salts of said tyrosine derivatives with pharmaceutically acceptable acids.Type: GrantFiled: February 3, 1975Date of Patent: January 18, 1977Assignee: Rotta Research Laboratorium S.p.A.Inventors: Francesco Makovec, Luigi Rovati, Paolo Senin
-
Patent number: 3985878Abstract: Anti-inflammatory antirheumatic compounds of the formula: ##SPC1##Wherein n.sub.1 and n.sub.2 are each either 2 or 3, and wherein the two tertiary amino-groups may, if desired, be present in the form salified by a pharmaceutically acceptable acid such as oxalic, citric, maleic, fumaric or hydrochloric acid. The preferred compound is N'-2-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indoleacetoxy]-ethyl-N-3-(N -benzoyl-N',N'-di-n-propyl-DL-isoglutaminoyl)-oxypropyl-piperazine, preferably in the form of dimaleate.Type: GrantFiled: July 10, 1975Date of Patent: October 12, 1976Assignee: Rotta Research Laboratorium S.p.A.Inventors: Francesco Makovec, Paolo Senin, Luigi Rovati